ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Conditions

Subcategories:Axial SpondyloarthritisClinical Criteria/GuidelinesGout and Crystalline ArthritisMyositisOsteoarthritis and Bone DisordersOther Rheumatic ConditionsPain SyndromesPediatric ConditionsPsoriatic ArthritisRheumatoid ArthritisSjögren’s DiseaseSoft Tissue PainSystemic Lupus ErythematosusSystemic SclerosisVasculitis

New ACR/EULAR IgG4 Classification Criteria Introduced

Arthritis & Rheumatology  |  January 2, 2020

Immunoglobulin G4-related disease (IgG4-RD) can cause fibroinflammatory lesions in nearly any organ. Correlation among clinical, serologic, radiologic and pathologic data is required for diagnosis. ACR/EULAR classification criteria for IgG4-RD have now been developed and validated in a large cohort of patients…

Baby on Board: The Rheumatologist’s Role in Family Planning for Patients with Lupus

Jason Liebowitz, MD, FACR  |  January 2, 2020

For patients with lupus, family planning discussions are vital to achieving positive pregnancy outcomes & maintaining overall health…

Immunoassay May Help Identify Pediatric Lyme Arthritis

Marilynn Larkin  |  December 18, 2019

NEW YORK (Reuters Health)—In Lyme disease-endemic areas, a C6 peptide enzyme immunoassay (EIA) test may help guide initial management of children with acute arthritis, an observational study suggests.1 “Children with Lyme disease frequently present to the emergency department with an inflamed joint,” Lise Nigrovic, MD, MPH, of Boston Children’s Hospital tells Reuters Health by email….

Ankylosing Spondylitis & Uveitis: An Ophthalmologist’s Perspective

Jason Liebowitz, MD, FACR  |  December 18, 2019

It’s often said the eyes are the window to the soul, and in the case of ankylosing spondylitis and other spondylo­arthropathies, one can also say the eyes are the window to systemic disease. Although uveitis occurs in approximately 2–5% of patients with inflammatory bowel disease, 6–9% of patients with psoriatic arthritis and 25% of patients…

Hair dye being applied to a man’s beard.

Case Report: A 50-Year-Old Man Suffers Dye-Induced Arthritis

Hrudya Abraham, MD, Eric Warm, MD, FACP, & Avis Ware, MD  |  December 18, 2019

Hair dye products are commonly used by both men and women to enhance youth and beauty and to follow fashion trends. As reported in the medical literature, hair dyes and their ingredients are associated with allergic contact dermatitis. A possible association with joint inflammation has also been recognized. There is literature to support that para-phenylenediamine…

FDA Approves Nintedanib for SSc-ILD, But Temper Your Expectations

Michael Putman, MD  |  December 18, 2019

The U.S. Food & Drug Admin­istration (FDA) approved nintedanib for systemic sclerosis associated interstitial lung disease (SSc-ILD) on Sept. 6 after a randomized, controlled trial (SENSCIS) demonstrated significant benefit against placebo.1 At a cost of $96,000 per year, treatment reduced the adjusted annual rate of change in forced vital capacity (FVC) from –93.3 mL in…

Remote Use of the Multidimensional Health Assessment Questionnaire (MDHAQ)

Juan Schmukler, MD, & Theodore Pincus, MD  |  December 18, 2019

The patient medical history is far more prominent in clinical decisions for rheumatology than for many common chronic diseases in which a gold standard biomarker, such as blood pressure or serum glucose, is applicable to diagnosis and management of all individual patients.1 Components of a subjective patient history may be recorded as structured, quantitative, standard,…

GPA & Relapsing Polychondritis Discussed

Mike Fillon  |  December 13, 2019

Challenges related to diagnosing chondritis are discussed.

Sicca Sleuthing: Clinical Pearls for Diagnosing & Treating Sjögren’s Syndrome

Jason Liebowitz, MD, FACR  |  December 13, 2019

ATLANTA—Dry eyes and mouth are common symptoms in the general population. When patients report these symptoms to their primary care provider and other consultants, it may prompt a referral to a rheumatologist to rule out Sjögren’s syndrome. However, as discussed in the 2019 ACR/ARP Annual Meeting session, Sjögren’s Syndrome: Beyond the Dryness, evaluation of this…

ANCA Mortality: Are Patients Doing Better?

Lara C. Pullen, PhD  |  December 13, 2019

Patients with anti-neutrophil cytoplasmic antibody–associated vasculitides (AAV) have an increased risk of mortality. But treatments have evolved in recent years. Recent research found that between 1999 and 2017 the AAV mortality rate declined by nearly 2% per year in patients 65–74 years old…

  • « Previous Page
  • 1
  • …
  • 111
  • 112
  • 113
  • 114
  • 115
  • …
  • 348
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences